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Abstract
Background: Skin prick test (SPT) and fluorescence enzyme immunoassay (FEIA) are widely used for the diagnosis
of Immunoglobulin-E (IgE)-mediated allergic disease. Basophil activation test (BAT) could obviate disadvantages of
SPT and FEIA. However, it is not known whether BAT gives similar results as SPT or FEIA for aeroallergens.
Objectives: In this study, we compared the results of SPT, BAT and FEIA for different aeroallergens.
Methods: We performed BAT, SPT and FEIA in 41 atopic subjects (symptomatic and with positive SPT for at least 1
of 9 common aeroallergens) and 31 non-atopic subjects (asymptomatic and with negative SPT).
Results: Correlations between SPT and BAT, SPT and FEIA, and BAT and FEIA results were statistically significant but
imperfect. Using SPT as the “gold standard”, BAT and FEIA were similar in sensitivity. However, BAT had lower
specificity than FEIA. False positive (BATposSPTneg) results were frequent in those atopic subjects who were allergic
by SPT to a different allergen and rare in non-atopic subjects. The false positivity in atopic subjects was due in part
to high levels of serum Total-IgE (T-IgE) levels in atopic individuals that lead to basophil activation upon staining
with fluorochrome-labeled anti-IgE.
Conclusion: As an alternative to SPT in persons allergic to aeroallergens, BAT in its present form is useful for
distinguishing atopic from non-atopic persons. However, BAT in its present form is less specific than FEIA when
determining the allergen which a patient is allergic to. This is due to IgE staining-induced activation of atopic
person’s basophils and/or nonspecific hyperreactivity of atopic person’s basophils.
Keywords: Allergic disease, Basophil activation test, Fluorescence enzyme immunoassay, Skin prick test, Aeroaller-
gen, Immunoglobulin-E
Background
Allergen-specific IgE-mediated inflammation is thought
to play a major role in the pathogenesis of allergic dis-
eases including extrinsic asthma, rhinitis or eczema. Fc
receptors of IgE bind to basophils and mast cells. Cross-
linking of the bound IgE by allergens induces the release
of inflammatory mediators. Skin prick testing (SPT) is
an indirect measure of specific IgE bound to skin mast
cells [1]. It has been widely used for the diagnosis of
allergic disease because the results are available quickly.
However, the utility of SPT is limited in patients with
rash or dermographism or those taking antihistamines
[2,3]. An alternative to SPT is the determination of
serum concentration of specific IgE using the radioaller-
gosorbent test (RAST) or the fluorescent enzymoimmu-
noassay (FEIA) [4]. A theoretical disadvantage of RAST
or FEIA is that it measures both functional IgE (capable
of binding to Fcε receptor I [FcεRI] on mast cells or
basophils and activating them) and nonfunctional IgE.
Another disadvantage of RAST or FEIA is that results
are not available as quickly as with SPT.
Basophil activation test (BAT), if shown to be clini-
cally useful, could be automated to the point of giving
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results within one hour. Moreover, it could theoretically
give a more relevant result than RAST or FEIA as only
functional IgE (capable of binding to and stimulating
basophils) is measured. In the older version of the test,
histamine or sulphidoleukotriene release from basophils
upon surface-bound IgE crosslinking was measured,
which correlated with bronchial provocation test results
in asthmatics [5]. In the newer, flow cytometry-based
version, a molecule whose expression is up-regulated on
basophil surface upon activation (eg, CD63 or CD203c)
is detected as a surrogate of inflammatory mediator
release [4,6-9]. This is less laborious and faster than sul-
phidoleukotriene release. On the other hand, Basophil
histamine release assay is also faster and automated but
can be used only if automated fluorimetry is available.
BAT could in some settings be more relevant for the
diagnosis of allergic disease than SPT, as allergic inflam-
mation might be mediated by basophils independently
of mast cells [10]. Indeed, BAT has been reported to be
more sensitive or specific than SPT or RAST/FEIA for
allergy to drugs, latex and venoms [11-15]. Here we




The study was approved by the Ethics Committee of the
University of Calgary. Atopic subjects were recruited by
allergists (B.S. or T.B.) among patients newly referred to
their allergy clinics. Of 45 subjects with symptoms of
asthma, rhinitis or eczema recruited, 41 were SPTpos to
at least 1 of 9 aeroallergens tested and studied as “atopic
subjects”. Their median age was 26 years (range, 18-69
years). Asymptomatic subjects (without symptoms of
asthma, rhinitis or eczema) were recruited by advertis-
ing. Of 42 asymptomatic subjects recruited, 31 were
SPTneg for all 9 aeroallergens tested and studied as
“non-atopic subjects”. Their median age was 29 years
(range, 15-47 years). To ensure uniformity in assessing
the presence of symptoms of asthma, rhinitis or eczema
between the symptomatic and asymptomatic persons,
the International Study of Asthma and allergies in
Childhood questionnaire (version Phase II, http://isaac.
auckland.ac.nz/PhaseOne/Manual/ManFrame.html,
accessed December 27, 2007) was used for both the
symptomatic and asymptomatic subjects. A written
informed consent was obtained from all the subjects.
Presence of symptoms was defined as a positive answer
to question # 2 (Have you had wheezing or whistling in
the chest in the last 12 months?), #7 (In the last 12
months, has your chest sounded wheezy during or after
exercise?) or #8 (In the last 12 months, have you had a
dry cough at night, apart from a cough associated with
a cold or chest infection?) of the asthma section;
question # 2 (In the past 12 months, have you had a
problem with sneezing, or a runny, or blocked nose
when you did not have a cold or the flu?) of the rhinitis
section or question # 2 (Have you had this itchy rash at
any time in the last 12 months?) of the eczema section
of the questionnaire. None of the subjects had cancer,
autoimmune disease or immunodeficiency, and none
had ever received allergen immunotherapy, systemic
immunosuppressive drugs in the past 3 months or anti-
histamines in the 7 days prior to SPT. None of the
patients were treated with omalizumab before blood
sample collection. Blood was drawn for BAT and FEIA
prior to SPT (typically within one hour prior to SPT) to
eliminate the possibility of SPT influence on the result
of BAT or FEIA.
Allergens
Allergen extracts (ALK-Abello, Horsholm, Denmark,
except for Timothy grass pollen extract from Greer
Laboratories, Lenoir, NC, USA) were kindly donated by
Western Allergy, Mississauga, Ontario, Canada. Neat
extracts contained 50% glycerol and 0.4% phenol. Nega-
tive control was 0.9% sodium chloride in 50% glycerol
and 0.4% phenol (Glycerol Saline). Positive control was
histamine 1 mg/mL in 50% glycerol and 0.4% phenol
(Histatrol, [ALK-Abello, Horsholm, Denmark]) for skin
prick test and anti-FcεRI (Alpco Diagnostics, Salem,
NH, USA) for BAT. The allergen concentration used for
SPT was in compliance with the US guidelines on prob-
able effective concentration range for allergen extracts
(http://www.aaaai.org/professionals/resources/immu-
notherapy/, accessed on November 26, 2009). The aller-
gen concentration used for BAT was based on our
preliminary experiments in which BAT was performed
for each allergen using five different concentrations - 5-
times, 10-times, 50-times, 100-times and 1000-times
lower concentration than that used for SPT. The 100-
times lower concentration was associated with the high-
est percentage of stimulated (CD63+) basophils above
Glycerol Saline background. The final concentration of
all 9 allergens used for SPT and BAT is mentioned in
Table 1:
Skin Prick Testing
Allergens and positive and negative control drops were
applied on the volar forearms with at least 2 cm dis-
tance from each other. For each allergen, a single epicu-
taneous prick was performed using Allersharp® device
(Western Allergy, Mississauga, Ontario, Canada). Wheal
area was recorded for Histatrol at 10 min, and for
others (each allergen and negative control) at 15 min by
outlining the area with a felt-tipped pen, and transfer-
ring the outline onto 3 M tapes to keep a permanent
record of SPT. The recorded wheal areas were scanned
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as jpeg files and analyzed by Image J software (National
Institutes of Health, Bethesda, MD, USA) to determine
the average diameter of each wheal. The average dia-
meter of the negative control wheal was subtracted from
each allergen wheal (corrected diameter). The SPT
result was considered positive if the corrected diameter
was greater than 3 mm compared to a negative saline
control [16]. All subjects had a valid SPT as defined by
at least 1 mm diameter difference between the positive
and negative controls [16].
Basophil Activation Test
Twenty mL of heparinized peripheral blood were centri-
fuged to obtain buffy coat cells, which were suspended
in interleukin-3 (IL-3)-containing buffer (Alpco Diag-
nostics, Salem, NH, USA). The suspension (100 uL) was
incubated with allergen (see “Allergens”, above, for con-
centration) or negative control (Glycerol Saline) or posi-
tive control (anti-FcεRI) for 25 min at 37°C in
humidified atmosphere. Then the cells were stained for
30 min at 4°C with the following fluorochrome-labeled
antibodies: IgE-FITC (Serotec, Raleigh, NC, USA),
CD63-PE (Beckman Coulter, Mississauga, Ontario,
Canada), CD123-PECy5 (BD Biosciences, San Jose, CA,
USA), and CD3-APC, CD8-APC, CD14-APC, CD19-
APC, and HLA-DR-APC (Beckman Coulter, Missis-
sauga, Ontario, Canada). Red blood cells were lysed
using ammonium chloride lysis buffer. After washing
and resuspending the cells in PBS with 1% bovine
serum albumin and 0.1% sodium azide, the cells were
analyzed by flow cytometry (FACS Aria, BD Biosciences,
San Jose, CA, USA). The number of events acquired
was set to contain at least 200 basophils (expressing IgE
and CD123 and not expressing CD3, CD8, CD14, CD19
or HLA-DR). Percent activated (CD63+) basophils were
expressed for each allergen. This percentage was cor-
rected for nonspecific activation by subtracting the per-
cent activated (CD63+) basophils in the negative control
(Figure 1). If the corrected percentage was at least 15%
for cat and timothy, 25% for DP, and 30% for dog and
birch, BAT for that allergen was considered positive (for
rationale, see results).
To evaluate whether staining of basophils for cell sur-
face-bound IgE with fluorochrome-labeled anti-IgE
induces CD63 upregulation, we performed BAT both
with and without fluorochrome-labeled anti-IgE (Figure
2). In the version without the anti-IgE, basophils were
identified as cells expressing CD123 and not expressing
CD3, CD8, CD14, CD19 or HLA-DR. The percentages
of activated (CD63+) basophils yielded by the two ver-
sions of staining were compared in 14 subjects (8 atopic
and 6 non-atopic).
Fluorescent enzymoimmunoassay
Sera from the research subjects were stored in tightly
sealed vials at -86°C. Near the end of the study, allergen-
specific IgE concentration was determined using Uni-
CAP100 instrument and specific IgE FEIA reagents (Pha-
dia, Uppsala, Sweden, accessed January 7, 2008) per
manufacturer instructions. For economy, IgE for only the
most common allergens was tested: Cat epithelium and
dander (e1), Dog epithelium (e2), D. pteronyssinus (d1),
D. farinae (d2), Timothy grass pollen (g6), and Birch tree
(Betula verrucosa) pollen (t3). Allergen-specific IgE FEIA
values of 0.1 kU/L or higher were considered positive.
Measurement of Total-IgE
Total-IgE (T-IgE) was measured in the sera of 36 atopic
and 28 non-atopic individuals on the Roche Elecsys
2010 analyzer by electro-chemiluminescence immunoas-
say using the manufacturer’s recommended operating
procedures, reagents and calibrations (Roche Diagnostics
Canada, Laval, QC).
Statistics
Correlations were analyzed using Spearman’s rank order
correlation coefficient test. Significance of difference of
test results between 2 subject groups was tested using
Mann-Whitney-Wilcoxon rank sum test. The choice of
a non-parametric test to compare two groups (Mann-
Whitney-Wilcoxon rank sum test) was based on the fact
that data distribution in at least one of the group in all
but one comparison was non-Gaussian. In order to
maintain the consistency, Mann-Whitney-Wilcoxon
rank sum test was used for all comparisons. In the
experiments comparing the effect of IgE staining on
CD63 upregulation, Wilcoxon matched paired test was
used to test significance of difference between the sub-
ject groups stained with or without IgE.
Two-tailed P values less than 0.05 were considered
significant.
Table 1 Concentration of allergens used for SPT and BAT
Allergen Concentration of the allergen
SPT BAT
Cat pelt 10,000 BAU/ml 100 BAU/ml
Dog epithelium 1:20 1:2000
Dermatophagoides pteronyssius (DP) 1000 AU/ml 100 AU/ml
Dermatophagoides farinae (DF) 1000 AU/ml 100 AU/ml
Alternaria 1:10 1:1000
Hormodendrum/Cladosporium 1:10 1:1000
Timothy grass pollen 100,000 AU/ml 1000 AU/ml [BAT]
Short ragweed pollen 1:20 1:2000
Birch tree (Betula verrucosa) pollen 1:20 1:2000
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Results
Of the 72 subjects (41 atopic and 31 non-atopic sub-
jects), 67 (93%) were evaluable for BAT (39 atopic and
28 non-atopic). The remaining 5 subjects (2 atopic and
3 non-atopic) were not evaluable because of unrespon-
sive basophils (less than 15% basophils expressing CD63
above background upon stimulation with anti-FcεRI
[positive control]). The subjects with unresponsive baso-
phils were eliminated from data analysis. Of the 39 eva-
luable atopic subjects, 11 (28%) had asthma, rhinitis and
eczema, 13 (33%) had asthma and rhinitis, 3 (8%) had
rhinitis and eczema, 9 (23%) had rhinitis only, 2 (5%)
had asthma only, and 1 (3%) had eczema only. By SPT,
19 (49%) of the 39 evaluable atopic subjects were aller-
gic to cat, 14 (36%) to dog, 11 (28%) to Dermatopha-
goides(D) pteronyssinus, 8 (20%) to Derpmatophagoides
(D) farinae, 2 (5%) to Alternaria, 2 (5%) to Hormoden-
drum, 26 (67%) to Timothy grass, 21 (54%) to birch tree
and 10 (26%) to short ragweed. Median number of posi-
tive skin prick tests per atopic subject was 2. Given the
small number of subjects atopic to D.farinae, Alternaria,
Hormodendrum and short ragweed, only analyses perti-
nent to cat, dog, D.pteronyssimus, Timothy grass and
birch tree are presented here.
Correlation between BAT and SPT and between FEIA and
SPT
Correlations between BAT and SPT results for all 5
allergens tested were statistically significant but imper-
fect, as correlation coefficients ranged from 0.37 to 0.54
(Table 1). Correlations between FEIA and SPT results
were also statistically significant; the correlation coeffi-
cients were consistently higher than for BAT and SPT,
ranging from 0.42 to 0.77 (Table 2).
Comparison of specificities of BAT and FEIA
To formally compare the specificity of BAT and FEIA
(using SPT as the “gold standard”), we first set the cut-
offs for BAT positivity for each allergen in such a way
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Figure 1 Example of basophil activation assay. Buffy coat cells suspended in an interleukin-3 (IL-3)-containing buffer were stimulated with (a)
negative control (Glycerol Saline); (b) positive control (anti-FcεRI) and (c) Timothy allergen. Basophills were defined as cells not expressing CD3,
CD8, CD14, CD19 or HLA-DR (P2) and expressing CD123 and IgE (P3). Activated basophils were defined as CD63+ basophils (P4).
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We used BAT receiver operating characteristic (ROC)
curves for choosing the cutoffs (Figure 3). Thus, the
sensitivities of BAT and FEIA were intentionally simi-
lar (Table 1). Then we calculated the specificities,
using the same cutoffs. For all 5 allergens, the specifi-
city of BAT was lower than the specificity of FEIA
(Table 2) due to a relatively high number of BAT-
posSPTneg results.
A- Allergen (Birch) B- Negative control
FSc
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Figure 2 Basophil activation assay performed (1) with or (2) without IgE staining. Buffy coat cells suspended in an IL-3-containing buffer
were (A) stimulated with birch allergen or (B) not stimulated (negative control - Glycerol Saline). Subsequently, the cells were stained with (1)
IgE-FITC, CD63-PE, CD123-PC5, and HLA-DR/CD3/CD19-APC or (2) IgG1 Mouse Isotype Control-FITC, CD63-PE, CD123-PC5, and HLA-DR/CD3/
CD19-APC. Basophills were defined as cells that do not express CD3, CD8, CD14, CD19 or HLA-DR (P2), but express CD123 (P3). Activated
basophils were defined as CD63+ basophils (P4). Density plot displaying only P4 is shown for the negative control for both versions of staining
(with or without IgE). Percentages of activated basophils are shown in the respective P4 gates. Corrected percentage of activated basophils was
calculated by subtracting saline control percentage from allergen stimulated percentage of activated (CD63+) basophils. In this example, the
corrected percentage of activated basophils on stimulation with Birch is 37.4% (38.4-1.0%) when anti-IgE was used for basophil staining and is
13.7% (14.2-0.5%) when anti-IgE was not used for basophil staining.
Table 2 Correlation between SPT and BAT, SPT and FEIA, and BAT and FEIA results, and sensitivity* and specificity**
of BAT and FEIA using SPT as the “gold standard”.
SPT vs BAT SPT vs FEIA BAT vs FEIA BAT sensitivity FEIA sensitivity BAT specificity FEIA specificity






.84 .84 .73 .83






.57 .64 .81 .92






.63 .63 .76 .87






.80 .80 .80 .82






.57 .61 .76 .93
* Calculated as the number of persons allergic for that allergen by both SPT and BAT or FEIA/total number of persons allergic for that allergen by SPT.
** Calculated as the number of persons nonallergic for that allergen by both SPT and BAT or FEIA/total number of persons nonallergic for that allergen by SPT.
Persons nonallergic for that allergen by SPT included both asymptomatic persons with negative SPT for all 9 allergens as well as symptomatic persons with
positive SPT for allergen(s) other than the allergen of interest.
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Figure 3 Receiver operating characteristics (ROC) curves used for the determining the cutoffs for positive BAT results. Sensitivity and
Specificity of BAT was calculated using different cutoffs (10%, 15%, 20%, 25% and 30% above background) for positivity. The cutoffs at which
sensitivity of BAT was similar to FEIA were selected. Selected cutoff value included 15% above background for Cat and Timothy, 25% for DP and
30% for Dog and Birch.
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Further, we reanalyzed the data with allergen-specific
IgE FEIA values of 0.35 kU/L or higher being considered
positive. Accordingly, the cutoffs for BAT positivity were
selected by plotting ROC curves to keep the sensitivities
of BAT and FEIA were similar. However, consistent
with earlier results, the specificity of BAT for all 5 aller-
gens was found lower than the specificity of FEIA
(Additional File 1).
BATposSPTneg ("false positive”) results were frequent in
atopic but infrequent in non-atopic individuals
The BATposSPTneg results were frequent in atopic sub-
jects who were SPTneg for the allergen of interest (but
SPTpos for another allergen) and rare in non-atopic sub-
jects (Figure 4, left). Also, median percentages of acti-
vated (CD63+) basophils were higher in the atopic
SPTneg subjects than the non-atopic subjects (the differ-
ence was significant for cat, dog and birch - Figure 4,
left), whereas median IgE levels by FEIA were similar in
the atopic SPTneg patients and the non-atopic persons
(Figure 4, right). Thus, the basophils of atopic indivi-
duals were more “excitable” (prone to upregulate CD63)
than basophils of non-atopic individuals.
Consistent with the nonspecific excitability of atopic
patients’ basophils, Figure 4 also shows that whereas the
difference in allergen-specific IgE was high between
SPTpos and SPTneg atopic patients (and significant for all
5 allergens), the difference in percent stimulated baso-
phils was relatively low between SPTpos and SPTneg ato-
pic patients (and significant for only 3/5 allergens). This
could be due to the fact that SPTpos patients were
defined as those having symptoms of asthma/rhinitis/
eczema (irrespective of exposure to an allergen) and
positive skin prick test to an allergen, but not necessa-
rily symptoms upon exposure to that allergen. Thus, we
re-analyzed the analyses presented in Figure 4, except
defined the SPTpos patients more strictly, ie, as patients
with symptoms of asthma/rhinitis/eczema AND positive
SPT for the allergen AND clinical history consistent
with allergy to that allergen (at a minimum, perennial
symptoms for a perennial allergen or seasonal symptoms
for a seasonal allergen). Even with this stricter definition
of SPTpos atopic patients, the difference in percent sti-
mulated basophils was relatively low between SPTpos
and SPTneg atopic patients (and significant for only 2/5
allergens) (Additional File 2).
Effect of anti-IgE staining on BAT results
A potential reason for the basophils of atopic individuals
being more “excitable” could be the following: The
staining of basophils with fluorochrome-labeled anti-IgE
could partially activate basophils by crosslinking IgE
(specific for any antigen) bound to basophils [17]. This
is generally thought to be negligible as the staining is
done at 4°C. However, if this is not negligible, basophils
of atopic individuals may be activated by the anti-IgE
staining to a significant degree whereas basophils of
non-atopic individuals to a nonsignificant degree. This
is because atopic individuals have on average ~10-fold
higher serum levels of total IgE (T-IgE) than non-atopic
individuals [18,19] and thus more IgE is expected to be
bound to basophils of atopic than non-atopic indivi-
duals. To evaluate whether the staining with anti-IgE
induces significant upregulation of CD63 on the baso-
phils of atopic individuals, we compared BAT results
performed with and without staining with fluoro-
chrome-labeled anti-IgE. Upregulation of CD63 on the
basophils of the atopic patients in case of those allergens
for which patients were not allergic to, was significantly
higher when cells were stained with fluorochrome-
labeled anti-IgE in comparison to the scenario when
cells were not stained with anti-IgE (P < 0.001, Figure 5,
right). This suggests that the anti-IgE staining induces
CD63 upregulation even at 4°C if a relatively large
amount of total IgE is bound to basophils. On the con-
trary, the BAT results were similar with and without
anti-IgE staining in the non-atopic individuals (Figure 5,
left); thus, CD63 may not be significantly upregulated by
the anti-IgE staining if only a small amount of total IgE
is bound to basophils. The results were similar with and
without anti-IgE staining also in the atopic patients in
case of allergens the patients were allergic to (Figure 5,
middle), suggesting that the stimulation through aller-
gen-induced crosslinking of specific IgE at 37°C is domi-
nant (not significantly enhanced by the anti-IgE
antibody-induced crosslinking of total IgE at 4°C).
Effect of total IgE levels on BAT results
As suggested in the above experiment (Figure 5), a
potential reason for the nonspecific increase in CD63
upregulation of basophils of SPTneg atopic individuals
compared to non-atopic individuals may be a high
amount of T-IgE in the SPTneg atopic individuals and
thus a high amount of T-IgE bound to the basophils of
the SPTneg atopic individuals. During staining of baso-
phils for surface-bound IgE with fluorochrome-labeled
anti-IgE, the high amount of T-IgE on basophils could
lead to nonspecific CD63 upregulation in the SPTneg
atopic individuals. To evaluate this hypothesis, we mea-
sured T-IgE levels in both atopic and non-atopic indivi-
duals (Figure 6). As expected, T-IgE levels were
significantly higher (p = 0.001) in atopic (median, 98.6
kU/L; range, 5.7 -1022.0 kU/L) than non-atopic (median,
16.4 kU/L; range, 0.2-245.8 kU/L) individuals. Among
SPTneg atopic individuals allergic to cat, dog, DP,
Timothy or birch, T-IgE levels were higher in BAT-
posSPTneg individuals than BATnegSPTneg individuals
(Figure 7). The difference was statistically significant for
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Figure 4 Results of BAT (left) and FEIA (right) in atopic patients (n = 39, squares and asterisks) and non-atopic persons (n = 28,
diamonds). The atopic patients are divided into those allergic to the allergen of interest per SPT result ("Atopic SPTpos“, squares) and those
allergic to a different allergen(s) ("Atopic SPTneg“, asterisks). The numbers of Atopic SPT+ patients were 19 for cat, 14 for dog, 11 for D.
pteronyssimus, 26 for Timothy, and 21 for birch. The numbers of Atopic SPTneg patients can be calculated for each allergen as 39 minus the
number of Atopic SPTpos patients (eg, 39-19 = 20 for cat). Significance of the difference between the Atopic SPTpos and Atopic SPTneg groups
and between Atopic SPTneg and Non-atopic groups is given in the upper section of each plot. BAT results are displayed as corrected percentage
of activated (CD63+) basophils (saline control percentage subtracted). Undetectable IgE levels by FEIA are displayed as 0.05 kU/L. Dashed lines
denote cutoffs for positivity. Cutoff for FEIA positivity was 0.1 kU/L, while that for BAT varied for different allergens - 15% above background for
Cat and Timothy, 25% for DP and 30% for Dog and Birch.
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cat (p = 0.01) and DP (p = 0.004) and marginally signifi-
cant for dog (p = 0.07), Timothy (p = 0.08) and birch (P
= 0.08). In conclusion, the increased reactivity of baso-
phils from SPTneg atopic individuals compared to non-
atopic individuals may be related to the high amount of
T-IgE bound to the their basophils.
Discussion
Our results suggest that BAT is as good as SPT or FEIA
for distinguishing atopic from non-atopic persons. How-
ever, in identifying the allergen to which an atopic per-
son is allergic, BAT in its present form appears to be
inferior to SPT or FEIA. When SPT is considered as the
“gold standard” and when the cutoffs are set so that
BAT and FEIA have similar sensitivities, BAT has lower
specificity than FEIA. The BATposSPTneg (false positive)
results are frequent in atopic but rare in non-atopic
individuals. This suggests that basophils from atopic
subjects are hyperresponsive to a nonspecific stimulus.
The results did not changed when we included the addi-
tional 5 subjects (2 atopic and 3 non-atopic) which were
not included in the primary analysis as they have unre-
sponsive basophils (less than 15% basophils expressing
CD63 above background upon stimulation with anti-
FcεRI (data not shown).
The nonspecific stimulus does not appear to come
from the IL-3-containing buffer, phenol or glycerol, as
the negative control BAT results were not higher in the
atopic subjects than in non-atopic subjects (median
10.1% vs 4.8% CD63+ basophils, P = 0.44) and because
BAT results were found similar when only saline was
compared with phenol and glycerol saline as a negative
control in three individuals (median 6.1% vs 7.8% CD63
+ basophils, P = 0.82). Consistent with that, in a pre-
vious report, IL-3 did not alter CD63 expression on
basophils incubated with IL-3 in the absence of allergen;
IL-3 only potentiated CD63 upregulation induced by
allergen [20]. Could the high occurrence of BATposSPT-
neg results in atopic patients be due to an intrinsic
hyperresponsiveness of atopic persons’ basophils? Posi-
tive control (anti- FcεRI) BAT results were not signifi-
cantly higher in the atopic subjects compared to non-
atopic subjects (median 59.2% vs 54.8% CD63+ baso-
phils above background, P = 0.66). This suggests that
either atopic person’s basophils are not intrinsically
hyperresponsive or that if they are intrinsically more
“excitable” than non-atopic persons’ basophils, this is
not apparent when a strong stimulus like anti- FcεRI is
used.
The nonspecific stimulus may be the staining of baso-
phils for surface-bound IgE with fluorochrome-labeled
anti-IgE. Atopic patients have higher serum levels of
total IgE than non-atopic individuals (Figure 6) [18,19].
The pair wise comparison of CD63 expression between
two versions of staining (with and without anti-IgE)
consistently showed a higher percent of activated (CD63
+) basophils (Figure 4, right) in the atopic SPTneg
patients when staining with anti-IgE. Thus, fluoro-
chrome-labeled anti-IgE can stimulate basophils coated
with IgE even if staining is done at 4°C. This appears to
be significant only in atopic patients and not non-atopic
individuals, possibly due to the presumed higher IgE
serum levels and thus higher density of basophil sur-
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Figure 5 Comparison of BAT performed with vs without IgE in healthy (non-atopic) persons and atopic patients. The atopic patients are
divided into those atopic to the allergen of interest per SPT result (middle) and those allergic to a different allergen(s) (right). Significance of the
difference between groups stained with and without IgE is given in the upper section of each plot. BAT results are displayed as corrected
percentage of activated (CD63+) basophils (saline control percentage subtracted).
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individuals. Use of a fixative like paraformaldehyde after
the stimulation and before staining, staining in a cal-
cium-free buffer, a blood wash before staining or use of
other basophil marker like CD203c may be helpful in
overcoming the non-specific stimulation due to IgE
staining [21-24].
The finding of significantly higher levels of T-IgE in




















Figure 6 Comparison of T-IgE levels in atopic patients and non-atopic individuals. T-IgE levels were measured in 36 atopic patients and 28
non-atopic individuals. Significance of the difference between the two groups is given in the upper section of the plot.
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(Figure 7) further supports the contention that the baso-
phils of SPTneg atopic individuals are overreactive due
to the high amount of basophil-bound IgE crosslinked
during staining with fluorochrome-labeled anti-IgE.
However, the hyperreactivity of atopic persons’ basophils
may not be due only to the activation by the fluoro-
chrome-conjugated anti-IgE, as 4 of 8 atopic patients
tested showed a high percentage (> 15%) of activated
basophils for SPTneg allergen(s) even when we used
staining without IgE. It should be determined whether
BAT could better discriminate the allergen to which a
patient is allergic to by using basophils from non-atopic
individuals (mixed with patient serum).
A limitation of this study is the fact that BAT and
FEIA were compared to SPT, which is not a definitive
diagnostic test, as 29-46% asymptomatic persons are
SPTpos for at least one of 10 common allergens,[25] and
some patients with provocation tests or clinical history
strongly suggesting allergic disease due to a specific
allergen and elevated serum levels of IgE to that allergen
are SPTneg for that allergen [26,27]. Thus, it is conceiva-
ble that at least some of the BATposSPTneg results repre-
sent false negative SPT rather than false positive BAT
results. Future studies could include bronchial or nasal
provocation tests as the “gold standard”. An alternative
would be to include intracutaneous testing in BAT-
posSPTneg patients. Allergen specific IgE may be more
specific than SPT [28], though defining a cut off point
for specific IgE levels to diagnose allergic disease has
been challenging [29]. As clinical history may represent
a better way of determining the clinical relevance of an
allergen [30,31], we compared the results of BAT and
FEIA for atopic individuals defined by clinical history in
addition of being SPTpos and having symptoms of symp-
toms of rhinitis/asthma/eczema. The results of this addi-
tional analysis (Additional File 2) were consistent with
BAT in its present form being less specific than FEIA
when determining the allergen to which a patient is
allergic.
It is also important to note that although negative
control BAT results were similar in atopic and non-ato-
pic subjects but this observation alone cannot comple-
tely rule out the role of IL-3 as a potent inducer of
CD63 upregulation. It is still possible that the addition
of IL-3 could also increase the sensitivity to allergens
that are seemingly negative in SPT or basophils from
atopic subjects might be responding directly to IL-3.








































































































Figure 7 Comparison of T-IgE levels in BATposSPTneg and BATnegSPTneg atopic patients. The numbers of SPTneg atopic patients analyzed
for T-IgE levels were 19 for cat, 24 for dog, 27 for D.pteronyssimus, 11 for Timothy, and 16 for birch. Significance of the difference between the
two groups is given in the upper section of the plot.
Khan et al. Allergy, Asthma & Clinical Immunology 2012, 8:1
http://www.aacijournal.com/content/8/1/1
Page 11 of 13
have not analyzed all BAT results with and without IL-3
which might have reduced the number of false-positive
BAT results.
Based on these results, we conclude that when SPT
is used as the “gold standard”, both BAT and FEIA
could distinguish an atopic from non-atopic persons,
but BAT is inferior to FEIA in distinguishing the aller-
gen to which an atopic person is allergic, from other
allergens for which the same atopic person is not aller-
gic. This is in part because basophils from at least
some atopic individuals appear to be nonspecifically
hyperresponsive, due at least in part to IgE bound to
basophils. It is important to mention here that we
have not measured the levels of Spleen tyrosine kinase
(Syk), a key regulatory factor in the IgE-mediated aller-
gic signal transduction pathway in mast cells and baso-
phils [32]. Theoritically, it is possible that
hyperresponsiveness of basophills may not be due to
the high levels of basophil-bound IgE but due to high
level of Syk. Another reason for the inferiority of BAT
as a diagnostic tests is the fact that it cannot be gener-
alized to the population since basophils of many indi-
viduals are unresponsive [7]. Further improvements of
the assay should focus on avoiding the anti-IgE stain-
ing induced basophil stimulation (eg, by staining fixed
basophils) or focus on basophil histamine release
instead of an up-regulation of CD63 as functional mar-
ker of basoiphil stimulation.
Additional material
Additional file 1: Sensitivity* and specificity** of BAT and FEIA
(positive cut off as 0.35 kU/L) using SPT as the “gold standard”.
Additional file 2: Results of BAT (left) and FEIA (right) in atopic
patients (n = 34, squares and asterisks) and non-atopic persons (n
= 28, diamonds) based on clinical history and SPT results. The atopic
patients are divided into those allergic to the allergen of interest per SPT
and clinical history ("Atopic SPTpos“, squares) and those allergic to a
different allergen(s) ("Atopic SPTneg“, asterisks). The numbers of Atopic
SPT+ patients were 15 for cat, 10 for dog, 8 for D.pteronyssimus, 22 for
Timothy, and 15 for birch. The numbers of Atopic SPTneg patients can be
calculated for each allergen as 34 minus the number of Atopic SPTpos
patients (eg, 34-15 = 19 for cat). Significance of the difference between
the Atopic SPTpos and Atopic SPTneg groups and between Atopic SPTneg
and Non-atopic groups is given in the upper section of each plot. BAT
results are displayed as corrected percentage of activated (CD63+)
basophils (saline control percentage subtracted). Undetectable IgE levels
by FEIA are displayed as 0.05 kU/L. Dashed lines denote cutoffs for
positivity. Cutoff for FEIA positivity was 0.1 kU/L, while that for BAT varied
for different allergens - 15% above background for Cat and Timothy, 25%
for DP and 30% for Dog and Birch.
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